
Nothing is final yet, but in all likelihood Meaningful Use Stage 2 won't kick in until 2014. In addition, some of the draft recommendations floating around look a lot like Stage 1 with stricter compliance levels. In other words: much of the work for Stage 2 is going to fall on EPs and hospitals, rather than on EMR vendors. There will likely be some new functionality -- especially around provider-patient communication -- but probably not the crush of requirements we saw in Stage 1.
So what will EMR, EHR, and HIS vendors do with their reprieve? If they're smart, they'll take this opportunity to improve their products in ways that aren't (yet!) required by Meaningful Use but which will give them an advantage in the market. Here's some functionality that EMRs may be using this reprieve to pursue:
- Implementing dose range checking: From a clinical point of view, this is one of the big gaps in what we've seen so far in the first two stages of Meaningful Use. Many of the news stories we read about adverse drug events aren't about interactions or allergies at all -- they're about mistakes in dosing. This is especially true with pediatric dosing, which can be extremely complicated. If dosage precautions were more widely implemented, patient safety would be positively affected.
- Addressing alert fatigue: Many EMR systems are likely to live or die based on this issue alone. Whoever can figure it out will have an undeniable benefit over the competition. As with many Meaningful Use issues, it starts with drug information vendors -- does yours provide the detail needed to make alerts intelligent?
- Improving patient education: The new recommendations for Stage 2 Meaningful Use are all about provider-patient communication. And transcripts of workgroups show that CMS and ONC are very interested in improving not just the method of communication, but the quality of information that flows through it. It seems likely that this will eventually include things like specific patient education materials for pediatric and adult patients, delivered in the language they primarily speak.
EMR vendors that can solve some or all of these issues now will find themselves ahead of the game when the next round of MU guidelines come out. Not only that, but they'll be delivering real value to clinicians that sets them apart from all the other cookie-cutter competitors who are simply "checking boxes" on the Meaningful Use checklist.
But where to start? Lexicomp is a drug and clinical information vendor who can help with all of the items listed above -- and with many more as well. Call or fill out a form today to start learning about how Lexicomp can help you build value for your users, save money and development resources, and meet government requirements for your EMR system.
I am reposting comments I made several months ago. Why? Because it is very important to build an EMR with the best pediatric dosing information possible. The implication are clear. So, if you are in the midst of building a new EMR or just want to include a link from your EHR over to Lexicomp Online's Pediatric Dose Range Checking, I would suggest reading this.
It might seem like an easy question, but the answer is neither obvious nor unimportant. Both pediatric and neonatal dose range calculators are receiving more focus and attention. This is serious business, with serious consequences. Last week, Matt Bennardo wrote a blog posting where he cited a study by Practice Fusion, where it has been shown that EHR's are having a real impact on the decrease in infant mortality. This is great news for those EHR's that have elected to use better dose range checking calculators.
As I said in a post last week. "All pediatric dosage calculators are not created equally. As Matt goes on to say, "But luckily there are drug information vendors like Lexicomp that understand there is a vast world of difference between adults and children -- and often between older children and neonates. Lexicomp's drug information is trusted by dozens of EHR vendors to guide clinicians in prescribing, fulfilling, and administering drugs to patients of all types -- including children."
Lexicomp provides both "machine readable" transactional information (geared towards specific populations) for use in clinical decision support, as well as "human readable" reference materials for clinicians and patients. Even Lexicomp's patient education leaflets are written with either adult or pediatric patients in mind.
If you are developing an EMR or looking to improve an EHR or HIS system, I would suggest reaching out to Lexicomp for some suggestions. Lexicomp is known for its pediatric and neonatal drug information.
In the last two years Lexicomp has quickly become a major provider of drug information to EMR companies for clinical decision support. Many of the new EMRs hitting the market are using Lexicomp medicine information for drug interactions, dose range checking, therapeutic dosages, adverse drug advents, electonic eprescring, and more. Lexi-Data has become the popular choice based on top quality information, unparalleled customer service, state-of-the-art data structure and top-notch APIs. Now something new!!
Lexi-Data has introduced a new structure which allows for the customization of Black Boxed Warning to reduce alert fatigue, yet at the same time delivers the warning to the person who needs it most. This information structure is new and as far as we know not available elsewhere.
API and Database Features:
- Incorporates not only the BBW as published within the package insert, but also pulls contextual or supporting information as written by Lexicomp clinical experts
- Each summary is broken down and tagged as separate messages / instructions
- Each message is paired to a recipient user category – this allow for differentiating where in the workflow of an EMR the message may be displayed
- Can be filtered for a more specific and targeted set of messages to clinician/recipient groups, as defined for their site
This is terrific stuff. So for anyone developing drug interaction software or eprescribing modules, this is something you will want to look into.
EMR vendors are not the only ones rapidly deploying clinical decision support systems to healthcare providers. Dental professionals are demanding that their practice management systems overcome massive development hurdles in order to comply with Meaningful Use standards.
There is a buzz in the dental technology community about Meaningful Use and incorporating more clinical decision support into the practice management system workflow. If you are searching for the best dental specific drug database to integrate into your dental EMR, turn to Lexicomp. There are very few suppliers of drug data within the dental market and even fewer still that are easy to work with. And if you are looking for an easy-to-use, out-of-the-box ePrescribing tool, trust our partner DoseSpot to deliver the solution. What do all of these companies have in common? They are easy to work with and provide you with the ability to get to the market fast!
Don't wait to the end of your development process to worry about: dose range checking, pediatric dosing, drug calculators, medicine interactions, dosage precautions, clinical guidelines, drug interaction software, duplicate therapy, drug classifications, generic drug names, drug nomenclature and more. These are critical paths for a dental EMR build. But it's not just about the information. It's about who you select as your partner and who has seamless API's which makes your development easier.
You owe it to your product and your customer to make the right choice.

Don't get discourgaged when looking for a drug data partner. Whether you have a laundry list of items or a small budget, Lexicomp has an intuitive database design that will help you seamlessly integrate complex drug reference databases into your system, allowing for easy implementation.
Other items that Lexicomp can help check off your list:
- Consumer-facing patient education materials in 19 languages
- Compliance with the RxNorm
- Dosage range checking, for both adult and pediatric
And many more!
Having a sick child can be a challenging and stressful time for any parent. A sick child also presents challenges for health care professionals as well as health information systems as it relates to prescribing medications. For a number of medications, pediatric dosage calculations are based on weight. Having a weight available in the community pharmacy setting is often challenging, however this is only the first step in being able to validate the correct dosage range. The second piece necessary to accurately check the validity of a pediatric prescription is having the correct information in your pharmacy system.
All too often, community pharmacy systems are not equipped with the necessary drug reference database to accurately evaluate a pediatric dose. For over 15 years, pediatric practitioners have been using Lexicomp's Pediatric Dosage Handbook and more recently, our electronic versions to prescribe and validate pediatric dosing. Now, this information has been transformed into a data set that can be integrated into pharmacy systems to allow your HIS to help you validate these critical doses. For more information about this product, visit http://www.lexi.com/businesses/ehr-vendors/.
It might seem like an easy question, but the answer is neither obvious nor unimportant. Both pediatric and neonatal dose range calculators are receiving more focus and attention. This is serious business, with serious consequences. Last week, Matt Bennardo wrote a blog posting where he cited a study by Practice Fusion, where it has been shown that EHR's are having a real impact on the decrease in infant mortality. This is great news for those EHR's that have elected to use better dose range checking calculators.
As I said in a post last week. "All pediatric dosage calculators are not created equally. As Matt goes on to say, "But luckily there are drug information vendors like Lexicomp that understand there is a vast world of difference between adults and children -- and often between older children and neonates. Lexicomp's drug information is trusted by dozens of EHR vendors to guide clinicians in prescribing, fulfilling, and administering drugs to patients of all types -- including children."
Lexicomp provides both "machine readable" transactional information (geared towards specific populations) for use in clinical decision support, as well as "human readable" reference materials for clinicians and patients. Even Lexicomp's patient education leaflets are written with either adult or pediatric patients in mind.
If you are developing an EMR or looking to improve an EHR or HIS system, I would suggest reaching out to Lexicomp for some suggestions. Lexicomp is known for its pediatric and neonatal drug information.
Find this out now or later, but is later to late? Not all drug reference databases are created equal. Drug data shapes everyday decisions in hospitals when dealing with patients. When developing or perhaps looking to improve upon your EMR, EHR, or HIS it is key to use drug data that meets qualifications and then some. What does this drug database look like you might ask?
A quality drug database should include:
- Interactions, including drug-drug, drug-allergy and drug-disease
- Dosage range checking, for both adult and pediatrics
- Duplicate therapy
- Compliance with RxNorm
An even better drug database will include:
Lexicomp not only provides drug data that meets the above criteria, but also more! Lexicomp provides customer service that is top notch and prepared to meet your needs at every level. Don't take my word though,
"Every time I call or email Lexi-Comp with a question, the service is like no other. I can't think of one single product that I have that continues to get better and better every year, except for Lexi-Comp. Ever since I started using Lexi-Comp, I can't imagine going to work as a pharmacist without it. I would be lost."
- Corey Duteau, Pharmacist
Matt Bennardo had a great blog post last week where he wrote about the positive benefits of Meaningful Use on the development of EHRs and their impact on patient safety. He cites a study by Practice Fusion, where it has been shown that EHR's are having a real impact on the decrease in infant mortality. This is great news!
As Matt wrote, "Of course, to get these kinds of results, the information in the EHR needs to be accurate, timely, complete, actionable, and specific to the patient. With respect to pediatric and neonatal patients, that last point is especially important. An EHR that is only set up to perform dose range checking and interaction checking on adults won't be nearly as helpful when it comes to children."
All pediatric dosage calculators are not created equally. As Matt goes on to say, "But luckily there are drug information vendors like Lexicomp that understand there is a vast world of difference between adults and children -- and often between older children and neonates. Lexicomp's drug information is trusted by dozens of EHR vendors to guide clinicians in prescribing, fulfilling, and administering drugs to patients of all types -- including children.
Lexicomp provides both "machine readable" transactional information (geared towards specific populations) for use in clinical decision support, as well as "human readable" reference materials for clinicians and patients. Even Lexicomp's patient education leaflets are written with either adult or pediatric patients in mind.
If you are developing an EMR or looking to improve an EHR or HIS system, I would suggest reaching out to Lexicomp for some suggestions.
Reports are circulating that spending on healthcare IT is set to grow at an annual rate of 24% over the next several years. This is phenomenal growth, and it's tempting to think that rising tides are going to raise everybody's boat. But with the proliferation of EHR vendors we've seen in the past couple of years, that conventional wisdom isn't likely to hold true. How do you make sure that you're one of the rising boats, and not one of the swamped ones?
Development talent is the scarcest resource right nowAmong other things, this boom in healthcare IT means more competition for talented developers with healthcare-specific experience. And the influx of cash means that a few well-funded or well-positioned EHR vendors are going to reap early rewards -- and then will likely start poaching even more top talent from other vendors by offering bigger salaries and more benefits.
Your best move is to protect your IT resources by having them focus only on the most crucial parts of your system -- the parts that will differentiate you in the marketplace. Use a drug information provider with robust APIs, an intuitive data structure, and superior customer service to take the burden off your own development team so they can focus on more important tasks. One such vendor is Lexicomp, who has helped many customers get to market faster after less-than-positive experiences with other medication list vendors.
Another tactic is to forgo building your own eprescribing tool (which can take months to certify anyway), and instead use a standalone module like DoseSpot.
Meaningful Use still rules the day -- but look ahead to Stage 2 and beyondWith the government incentives now beginning to pay out, more and more practices and hospitals are pursuing Meaningful Use certification. To compete, your system will need to meet the Stage 1 requirements like drug-drug interaction checking, drug-allergy interaction checking, and distribution of patient education materials.
But it's not enough to simply check off the existing boxes. Every other EHR vendor is rushing to do the same. Instead, you need to provide value above and beyond the others. Again, a drug information vendor like Lexicomp can help you exceed Stage 1 requirements and put yourself where you need to be for Stage 2 and 3. They offer functionality like dosage range checking for both adults and pediatric patients, detailed patient education pamphlets in multiple languages, and links to some of the best drug and clinical reference services available.
Deploying extra features like these in your system can help make it more likely that you'll be a rising boat when the money starts pouring in.
What do all of these have in common? Well for one thing, they are being driven in part by the demands of Meaningful Use requirements.
Here is just one example of Meaningful Use effect. Some of the demands are actually in place, and many others roll out over the next few years. EPrescribing in Florida looks like it might be taking an interesting turn as free application provided by the State may be going away, or so I have heard. This recently
posted ePrecribing blog described it in greater detail. And
a second blog.
As Meaningful Use requirements have dictated more relevant application of medication and drug data within EMR and EHR systems, the awareness of the nuances of these databases has also gone up. Recognition of the following terms is becoming more commonplace: Drug Reference Database; Dosage Range, Dosing in Pediatrics, Drug Interaction List,
Pediatric Dosage Calculator, Medicine Interaction. Clinical Decision Support Systems, Drug Content, and more.
As we attempt to incorporate more technology into medicine through the use of HIS, it brings to light the need for more than just a simple medication list. Health information systems are now being asked to help improve patient outcomes by performing other clinical decision support functions that go beyond a pick list. If we truly want to improve patient outcomes, it is important that our HIS provide relevant clinical guidance especially in a critical population such as pediatrics. Calculating pediatric doses is not always an easy task and having data in your HIS that can perform pediatric dosing calculations can be an invaluable tool in improving patient outcomes.
Lexicomp has a long standing reputation of providing this valuable and often difficult dosing information in the Pediatric Dosage Handbook. For over 20 years, we have been providing neonatal and pediatric dosing based on available literature and current clinical practice. More recently this information has been transformed into Lexi-Data's Pediatric Dosage Range Checking application. This content can be used within an HIS to provide guidance to your clinicians on appropriate dosing for this difficult and vulnerable population.
The goal of policy makers in requiring the use of e-prescribing is to improve medication safety. Many systems have the ability to screen a new prescription for safety using clinical decision support tools such as drug interaction, drug allergy, duplicate therapy and dosage range checking. A recently published study by the Center for Studying Health System Change (HSC) analyzed the use of e-prescribing in physician practices and the impact on patient care. The study included 24 practices and found that while most e-prescribing systems used had access to patient medication information and clinical decision support tools built-in, only slightly more than half of the physicians reported accessing this information. Several reasons were cited for this low usage including the fact that it is difficult to import medication histories into the patient records and that physicians found little value in reviewing this information when making prescribing decisions.
The results of this study raise some interesting questions. The challenge of incorporating patient specific medication histories from multiple sources certainly is a real barrier and one that is pivotal to making CDS useful. Maybe more alarming is the perception that the alerts and checks that the system can provide are not useful in influencing prescribing decisions. This point can be challenging when e-prescribing systems are not built with reliable and clinically relevant data to power the CDS processes.
Lexicomp provides clinical information that can be used to perform key CDS functions such as drug interaction, drug allergy, duplicate therapy and dosage range screening. This content is derived from our well-established drug reference information that is evidenced-based, peer-reviewed and up-to-date. If you are a clinician working in health care, you most likely have relied on this content to help you make patient care decisions for many years. If CDS is going to accomplish its goal of improving patient care, it is going to require a strong, evidenced based library of clinical information. Something Lexicomp has been doing for over 30 years.
Hospitals are complex organizations with many different systems used by different departments, and often not well integrated. All kinds of errors can occur -- human errors, data-entry errors, labeling errors. And unfortunately, sometimes those errors have fatal consequences, such as this case of a premature infant that received a lethal dose of sodium due to a parenteral nutrition compounding error.
In this particular case, the death was reported to have led from incorrect data entry into the compounder, insufficient oversight by the pharmacist, incorrect labeling, and an unfulfilled physician request for investigation into abnormally high sodium levels in the infant. Though neither the EMR nor the CPOE were directly implicated in the error this time, it's always worth thinking about whether your system would have been capable of preventing this mistake -- and if not, what you may need to change.
Needed: Dose range checking -- and then some
In order for any system to have detected this error, some form of dose range checking would need to have been in place. This wasn't a result of an adverse drug event or an improperly prescribed medication, so Meaningful Use interaction and allergy checking are of no use. Only knowledge of the correct dosage for this specific patient would help.
In fact, not even all dose range checking would be helpful. This patient belonged to a special class -- a neonate. So the dose checking would need to be differentiated between adult and pediatric (or, in this case, neonatal). Otherwise, a dose that would be appropriate for an adult but fatal to an infant could easily be prescribed.
IV compatibility also an issue
This case also dealt with a solution administered intravenously. In this particular case, there was no adverse reaction between the ingredients being compounded, but with IV administration that's always a possible danger. Therefore, to be 100% safe, your EHR or HIS would also need to contain information about IV Y-site compatibility.
And of course, all of this would need to be checked and double-checked at every stage of the process by every clinician: the physician entering the order into the CPOE, the pharmacist compounding the solution, and the nurse administering it to the patient. The systems that each clinician uses should be able to check for each of these factors (and more!), and also should be able to provide the clinicians with more "human readable" information in case something doesn't seem right.
With the state of healthcare IT today, most of us are still a long way off from being able to implement a perfectly integrated system that can eliminate this kind of error entirely. But taking a few steps with the systems we have control over can reduce tragic outcomes like this one. One place to start is to contact a clinical and drug information vendor like Lexicomp to find out what information is available to be integrated into your systems -- both transactionally for automatic clinical decision support and as reference material for clinicians to make use of.
As hospitals and EMR vendors scramble to prepare for Stage I Meaningful Use criteria, the Stage II criteria are already being prepared. The Stage II requirements will require hospitals to continue with and advance the use of CPOE, and the use of clinical decision support elements including drug interaction and drug allergy screening. Additionally, patient education materials must be offered to at least 80% of patients at discharge.
Although most of these requirements are simply advancing a requirement from Stage I, the ultimate goal of requiring the use of clinical decision support tools is to improve patient care, especially as it relates to high priority health conditions. In order to accomplish this, CDS should have specific attributes: authenticated, credible, evidenced-based and patient-context sensitive. This can only be accomplished by using a drug reference database that can provide information that meets this criteria.
Lexicomp provides clinical information that can be used to perform key CDS functions such as drug interaction, drug allergy, duplicate therapy and dosage range screening. This content is derived from our well established drug reference information that is evidenced-based, peer-reviewed and up-to-date. If you are a clinician working in health care, you most likely have relied on this content to help you make patient care decisions for many years. If CDS is going to accomplish its goal of improving patient care, it is going to require a strong, evidenced based library of clinical information. Something Lexicomp has been doing for over 30 years.
Several institutions, as well as drug data vendors, have constructed dose range checking content. In many cases, the institutions have learned that this can be a difficult process to complete and maintain. Reliance on a drug reference book such as the Pediatric Dosage Handbook to create these data technically is outside of the terms of use, and leaves open the issue of maintenance and timely modification as new information appears in the literature.
Without a valid model to identify, acquire, evaluate, and publish. Dosage precautions which are not actively supported by this type of surveillance typically fall out of date rather rapidly. Pediatric dose calculations can be limited, and therapeutic dosages which are supported in the literature may be identified as outside the range. This type of over-alerting is a source of frustration. Lexicomp has worked with its partners to transform the content of the Handbook into a database with associated APIs to execute dose range checking for pediatrics. In addition, these data are actively modified in conjunction with the normal process of maintaining this publication. In this way, the user can integrate dose range checking simply, with the assurance that the data are continuously updated and expanded.
Are you an EMR or EHR vendor looking to enter the ambulatory care market? If so, now is the right time to capitalize on the expanded use of clinical decision support tools by these healthcare professionals. A recent article in Healthcare IT News states that "one third of physician practices and community health clinics are poised to replace their electronic medical records systems". Are you ready for the this onslaught of new business or are still trying to launch your system?
If you are lagging behind the development curve, a surefire way to enter the market faster is to partner with a proven leader in drug databases for clinical decision support systems. Lexicomp's integrated solutions help hospitals, EMRs, consumer websites and other health IT developers easily implement drug reference information and drug data into their systems. When integrated into HIS systems, Lexicomp solutions provide clinicians access to current and relevant drug information, and supply end users the functionality to support several aspects of clinical decision support required by an EMR for certification.
Whether you are looking for basic drug nomenclature, dosage range calculators, drug interaction software, or ePrescribing solutions, turn to Lexicomp to help you enter the ambulatory market faster!
Drug databases often have application programing interface tools that can alert a user to maximum or minimum dosages on a given medication. What can be even more valuable is the functionality to provide medication dosage precautions at the time of order entry and or the time of medication administration. There is much debate as to whether electronic medical records or drug database APIs should provide dosing ranges or actual expert dosing.
While expert dosing may be a desired tool, one must be cautious in evaluating the system behind such a tool as it will only be as accurate and sophisticated as its logic allows. Criteria that should be considered for either expert dosing or dose range checking includes renal and hepatic functionality of the patient, as well as the typical height, weight, age and sometimes sex.
Alerts that may result from the dose range checking of an order may contain more that the typical therapeutic dosage information, but may also contain some actionable medication dosage precautions. Does the drug require lab testing previous to administration or during it's use? Would the drug be better absorbed if the patient takes it with meals? Planning to include this type of information during the build of the EMR, and subsequently baking it into the maintenance process of adding new drugs, is essential.
As a result of a request made by someone who particularly liked one of my posts last month, I am reposting. This year at HIMSS should be pretty interesting, and maybe a bit chaotic and a little unsettling. Meaningful Use was getting bandied about last year, but this year it is real, tangible and around the corner.
Whether you are an EMR vendor, EHR manager, ePrescribing vendor, or someone else in this dynamic and quickly changing business segment, you will want to see what it is going on. One of the areas that is a bit overlooked and undervalued until you have signed a long-term agreement (and it is too late to reconsider) is in the area of drug database information for clinical decision support.
The data is important, but equally important is the relationship with your drug information provider. Once you make your selection, you will be "stuck" with them for a very long time. Make the right choice. Obviously, other areas for evaluation have to do with the level and sophistication of APIs that the vendor has or are under development.
Pediatric dosage calculations, drug interaction software, drug generic name, drug brand name, drug classifications, drug and medicine interactions, medicine lists, clinical guidelines, clinical information systems, and more, are all critical areas for consideration.
At HIMSS 2011 there will also be live demonstrations showing how our drug databases can be implemented and customized to meet the various specific needs of EMR vendors. Stop by and see us if you are a current customer or are looking to implement drug information or clinical decision support into your application, booth #6653.
Lexicomp will be attending HIMSS 2011 in Orlando. This will be a great opportunity for any EMR, Hospital, or Consumer Health Site to visit booth #6653 and learn about our solutions for implementing decision support for drug interactions, duplicate therapy, drug allergies, and dose range checking, as well as drug databases, and patient education information for consumers.
My colleague, Matt Bennardo, recently wrote a blog about discovering alternatives to the traditional providers of drug information data for EMRs and EHRs. He suggested that HIMSS this year will offer some choices to customers who are desperately looking beyond their few limited choices of the past.
Lexicomp showed last year at HIMSS and started getting the attention of many EMR companies. Throughout the course of 2010 this translated into many new customers and strong partnership relationships.
As Matt wrote:
"More EMRs are calling Lexi-Data their “preferred choice” every month
Many of our customers have told us that they’ve made the switch because they found Lexi-Data delivered:
- Better quality information with faster updates and fewer mistakes
- A more clinically relevant focus that their end users valued
- Easier implementation and more powerful functionality
- Superior customer service
- Unique content not available elsewhere, like Lexicomp’s industry-leading Pediatric Dose Range Checking
Lexicomp will be exhibiting at HIMSS 2011 in Orlando, Florida, from February 21 - 23. Stop by for a visit at Booth #6653 and learn more about the choices you have in drug information databases!"
So if you are looking for dosage administration, drug brand and generic names, therapeutic dosage information, medicine lists,or pediatric dosing information for EMRs, Emergency Room EMRs, EHRs and HIS systems, stop by the booth to learn more.